tetano
Editor, Senior Moderator
Br J Haematol
. 2020 May 20.
doi: 10.1111/bjh.16863. Online ahead of print.
Protective Role of BTK Inhibitors in Patients With Chronic Lymphocytic Leukemia and COVID-19
Santiago Thibaud[SUP] 1 [/SUP], Douglas Tremblay[SUP] 1 [/SUP], Sheena Bhalla[SUP] 1 [/SUP], Brittney Zimmerman[SUP] 1 [/SUP], Keith Sigel[SUP] 2 [/SUP], Janice Gabrilove[SUP] 1 [/SUP]
Affiliations
Abstract
Severe cases of coronavirus disease 2019 (COVID-19) are usually accompanied by an exuberant immune response comparable to cytokine release syndrome (CRS), with markedly elevated serum levels of proinflammatory cytokines which are thought to be a major drivers of morbidity and mortality for these patients (Huang, et al 2020). Several drugs with anti-inflammatory properties (tocilizumab, siltuximab, sarilumab, anakinra, among others) have been suggested as adjuncts to supportive care in the management of COVID-19, and several clinical trials are underway (NCT04315298, NCT04317092, NCT04306705).
Keywords: BTK inhibitors; CLL; COVID-19.
. 2020 May 20.
doi: 10.1111/bjh.16863. Online ahead of print.
Protective Role of BTK Inhibitors in Patients With Chronic Lymphocytic Leukemia and COVID-19
Santiago Thibaud[SUP] 1 [/SUP], Douglas Tremblay[SUP] 1 [/SUP], Sheena Bhalla[SUP] 1 [/SUP], Brittney Zimmerman[SUP] 1 [/SUP], Keith Sigel[SUP] 2 [/SUP], Janice Gabrilove[SUP] 1 [/SUP]
Affiliations
- PMID: 32433778
- DOI: 10.1111/bjh.16863
Abstract
Severe cases of coronavirus disease 2019 (COVID-19) are usually accompanied by an exuberant immune response comparable to cytokine release syndrome (CRS), with markedly elevated serum levels of proinflammatory cytokines which are thought to be a major drivers of morbidity and mortality for these patients (Huang, et al 2020). Several drugs with anti-inflammatory properties (tocilizumab, siltuximab, sarilumab, anakinra, among others) have been suggested as adjuncts to supportive care in the management of COVID-19, and several clinical trials are underway (NCT04315298, NCT04317092, NCT04306705).
Keywords: BTK inhibitors; CLL; COVID-19.